Tianjin Pharma posts 11 % net profit rise in Q3 2024

The group’s Chinese medicine segment primarily drove revenue, which contributed $807.8m.

Tianjin Pharmaceutical Da Ren Tang Group posted an 11% year-on-year (YoY) rise in net profit to $26.3m (RMB 141.9m) for Q3 2024, its bourse filing showed.

Revenue for the quarter was $304.5m (RMB 1.64b), reflecting a 3% decline from $315.7m (RMB 1.7b) in the same period in 2023. For the nine-month period, revenue totaled approximately RMB 5.6 billion, down 3.1% year-on-year due to weaker commercial sales.

The group’s Chinese medicine segment primarily drove revenue, which contributed $807.8m (RMB 4.35b). In comparison, the western medicine segment brought in $170.5m (RMB 918.2m), with other medicines contributing $69m (RMB 341.75m).

During the period, the company deregistered its wholly-owned subsidiary, Tianjin Zhongxin Chuyun Trading Co., Ltd., and acquired a 15% equity interest in Tianjin Pharmaceutical Group Finance Co. for $16.3m (RMB 87.82m).

As of September, the group’s dividend rate stands at $0.24 (RMB 1.28) per ordinary share.

(RMB 1 = $0.19)

Follow the link for more news on

Financial Statements

The people you want to reach are already in this room.

Every quarter, SBR lands on the desks of the founders, CFOs, and directors running Asia's most consequential companies. Every day, they open our newsletter and read our website. It's a room that took twenty years to build — and it's the one most of our partners are trying to get into.

The good news is that the door is open. We work with companies on thought leadership articles, sponsored content, industry summits across Southeast Asia, regional awards programmes, podcasts, and media placements in print and digital. The shape of the right partnership depends on what you're trying to do, which is why we'd rather start with a conversation than send a rate card.

If you have something this room should know about, tell us. We'll tell you honestly whether we can help, and how.

No rate cards until we understand the brief. It's a better use of everyone's time.

Book a meeting

| Or download the media kit (PDF)

240,000 senior readers quarterly in print Top 1,700 Singapore companies reached

7 markets across Southeast Asia